$52.77 -0.2 -0.3%
Last Trade - 09/04/21
| Market Cap | £2.68bn |
| Enterprise Value | £2.26bn |
| Revenue | £148.2m |
| Position in Universe | 1673rd / 6827 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 59.1 | 69.9 | 43.0 | 94.4 | 117.9 | 203.2 | 88.0 | 134.1 | +28.0% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | August 7, 2007 |
| Public Since | July 24, 2013 |
| No. of Shareholders: | 11 |
| No. of Employees: | 562 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 69,601,332 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 88 Sidney St, CAMBRIDGE, 02139-4137, United States |
| Web | http://www.agios.com/ |
| Phone | +1 617 6498600 |
| Contact | Holly Manning (IR Contact Officer) |
| Auditors | PricewaterhouseCoopers LLP |
As of 09/04/21, shares in Agios Pharmaceuticals Inc are trading at $52.77, giving the company a market capitalisation of £2.68bn. This share price information is delayed by 15 minutes.
Shares in Agios Pharmaceuticals Inc are currently trading at $52.77 and the price has moved by 32.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Agios Pharmaceuticals Inc price has moved by -10.81% over the past year.
Of the analysts with advisory recommendations for Agios Pharmaceuticals Inc, there are there are currently 3 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Agios Pharmaceuticals Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Agios Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:
Agios Pharmaceuticals Inc does not currently pay a dividend.
Agios Pharmaceuticals Inc does not currently pay a dividend.
Agios Pharmaceuticals Inc does not currently pay a dividend.
To buy shares in Agios Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Agios Pharmaceuticals Inc are currently trading at $52.77, giving the company a market capitalisation of £2.68bn.
Here are the trading details for Agios Pharmaceuticals Inc:
Based on an overall assessment of its quality, value and momentum, Agios Pharmaceuticals Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Agios Pharmaceuticals Inc are currently priced at $52.77. At that level they are trading at 22.97% discount to the analyst consensus target price of 0.00.
Analysts covering Agios Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -6.07 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agios Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been 27.83%. At the current price of $52.77, shares in Agios Pharmaceuticals Inc are trading at 18.08% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc's management team is headed by:
Here are the top five shareholders of Agios Pharmaceuticals Inc based on the size of their shareholding:
